Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 4,560 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: assessment only control Clear all

Conditions: Healthy Adult Subjects
Interventions: ONO-7746; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab, Antihistamine, Methylprednisolone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 24
States / cities: Homewood, Alabama • Phoenix, Arizona • Irvine, California + 21 more

Conditions: Chest Pain, Angina Pectoris, Myocardial Infarction
Interventions: coronary artery computed tomography angiogram, single photon emission computed tomography; Procedure
Lead sponsor: Corewell Health East; Other
Eligibility: 25 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Hypoparathyroidism
Interventions: Canvuparatide, Placebo; Drug · Other
Lead sponsor: MBX Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 21
States / cities: Englewood, Colorado • Homestead, Florida • Lawrenceville, Georgia + 18 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Medically Tailored Meals, Tele-Medical Nutrition Therapy (tele-MNT); Other · Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Myopia
Interventions: Single vision contact lenses, Multifocal contact lenses; Device
Lead sponsor: Visioneering Technologies, Inc; Industry
Eligibility: 7 Years to 13 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Fresno, California • Deerfield, Illinois • New York, New York + 1 more

Conditions: Adherence to Medication Regime, Cancer
Interventions: Mobile Application Intervention; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Boston, Massachusetts • Concord, Massachusetts

Conditions: Epidermolysis Bullosa (EB)
Interventions: SD-101 Dermal Cream (6%), Vehicle (SD-101 0%); Drug
Lead sponsor: Paradigm Therapeutics; Industry
Eligibility: 28 Days to 12 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Rancho Santa Margarita, California • Redwood City, California • Philadelphia, Pennsylvania + 1 more

Conditions: Physical Activity
Interventions: TXT Me; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 14 Years to 17 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: rosiglitazone maleate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Infra-orbital Hollows, Tear-trough Deformity, Wrinkle
Interventions: RHA® Redensity Eye; Device
Lead sponsor: Teoxane SA; Industry
Eligibility: 22 Years and older
Enrollment: 248 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Encino, California • Santa Monica, California • Coral Gables, Florida + 1 more

Conditions: Cystic Fibrosis, Contraception
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 562 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 7 more

Conditions: Pain, Pregnancy
Interventions: painDETECT Questionnaire, Pain Catastrophizing Scale, Pain Intensity Scale, Pain Interference Scale, Pain Behavior Scale, Beck Depression Inventory, Visual Analogue Scale, Patient's Global Impression of Change Scale & Clinical Global Impression-Global Improvement Scale, Transcranial Magnetic Stimulation; Behavioral · Device
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Osteoarthritis, Knee
Interventions: UBX0101, Placebo; Drug · Other
Lead sponsor: Unity Biotechnology, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: El Cajon, California • La Mesa, California • Miami, Florida + 4 more

Conditions: Second Hand Tobacco Smoke
Interventions: Smoke-free homes intervention; Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Diabetes Mellitus, Type 2
Interventions: SB-756050 immediate release capsule, SB-756050 modified release capsule, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Benign Prostatic Hyperplasia (BPH)
Interventions: NX-1207, Placebo; Drug
Lead sponsor: Nymox Corporation; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 35
States / cities: Laguna Hills, California • San Diego, California • Tarzana, California + 30 more

Conditions: Healthy
Interventions: NM8074, Placebo; Drug
Lead sponsor: NovelMed Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Subjects
Interventions: MGD010, Placebo, Hepatitis A vaccine; Drug · Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: Itopride; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 45 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pain, Postoperative, Total Knee Arthroplasty (TKA)
Interventions: Continuous Femoral Nerve Block, Nerve Block, Continuous Adductor Canal, Continuous Sciatic Nerve Block, Bupivacaine; Procedure · Drug
Lead sponsor: Kevin King, DO; Other
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Depression, Anxiety
Interventions: Lumen Treatment; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Obsessive Compulsive Disorder (OCD)
Interventions: Low Intensity Focused Ultrasound; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alcohol Use, Unspecified
Interventions: Deviance Regulation Theory; Behavioral
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years to 21 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Search by objective public record fields.

ONO-7746 Study in Healthy Adult Subjects

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Study of Coronary Artery Computed Tomography to Diagnose Emergency Chest Pain

A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism

Project MiNT: Assessing the Impact of Food & Video-Based Nutrition Education on Patients With Poorly Controlled Diabetes

Progressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial

Mobile Application for Improving Symptoms and Adherence to Oral Chemotherapy in Patients With Cancer

Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

Text Messages and Physical Activity Among Teens

Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate

RHA® Redensity Eye Versus No-treatment for the Infra-Orbital Hollows

Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis

Neuropathic Pain in Pregnancy

A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee

Implementing a Scalable Smoke-free Home Intervention in Armenia and Georgia

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers

Phase 1 Study of MGD010 in Healthy Subjects

A Study to Evaluate the Effect of a Medicine on Gastric Functions in Healthy Volunteers.

Continuous Adductor Canal Blocks Vs. Low Dose Femoral Nerve Blocks For Early Rehabilitation After Total Knee Arthroplasty

Study of a PST-Trained Voice-Enabled Artificial Intelligence Counselor (SPEAC) for Adults With Emotional Distress (Phase 1)

OCD LIFU Target Engagement

Longitudinal Use of Protective Behavioral Strategies